Phase I study of temozolomide in paediatric patients with advanced cancer
Authors:
- on the behalf of the United Kingdom Children's Cancer Study GroupOGon the behalf of the United Kingdom Children's Cancer Study Group
- L LashfordLLL Lashford
- S AblettSAS Ablett
- L PriceLPL Price
- R GowingRGR Gowing
- A GholkarAGA Gholkar
- J KohlerJKJ Kohler
- Ij LewisILIj Lewis
- B MorlandBMB Morland
- Cr PinkertonCPCr Pinkerton
- Mcg StevensMSMcg Stevens
Open Access
- 1 September 1998
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 78 (5) , 652-661
Abstract
A phase I study of temozolomide administered orally once a day, on 5 consecutive days, between 500 and 1200 mg m(-2) per 28-day cycle was performed. Children were stratified according to prior craniospinal irradiation or nitrosourea therapy. Sixteen of 20 patients who had not received prior craniospinal irradiation or nitrosourea therapy were evaluable. Myelosuppression was dose limiting, with Common Toxicity Criteria (CTC) grade 4 thrombocytopenia occurring in one of six patients receiving 1000 mg m(-2) per cycle, and two of four patients treated at 1200 mg m(-2) per cycle. Therefore, the maximum-tolerated dose (MTD) was 1000 mg m(-2) per cycle. The MTD was not defined for children with prior craniospinal irradiation because of poor recruitment. Plasma pharmacokinetic analyses showed temozolomide to be rapidly absorbed and eliminated, with linear increases in peak plasma concentrations and systemic exposure with increasing dose. Responses (CR and PR) were seen in two out of five patients with high-grade astrocytomas, and one patient had stable disease. One of ten patients with diffuse intrinsic brain stem glioma achieved a long-term partial response, and a further two patients had stable disease. Therefore, the dose recommended for phase II studies in patients who have not received prior craniospinal irradiation or nitrosoureas is 1000 mg m(-2) per cycle. Further evaluation in diffuse intrinsic brain stem gliomas and other high-grade astrocytomas is warranted.Keywords
This publication has 13 references indexed in Scilit:
- Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer.1997
- Phase II trial of temozolomide in low-grade non-Hodgkin's lymphomaBritish Journal of Cancer, 1995
- Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma.Journal of Clinical Oncology, 1995
- A comparison of two phase I trial designsStatistics in Medicine, 1994
- Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)British Journal of Cancer, 1992
- O6-methylguanine-DNA methyltransferase in human normal and tumor tissue from brain, lung, and ovary.1991
- ANTITUMOR IMIDAZOTETRAZINES .13. ANTITUMOR-ACTIVITY AND PHARMACOKINETICS IN MICE OF 8-CARBAMOYL-3-METHYL-IMIDAZO[5,1-D]-1,2,3,5-TETRAZIN-4(3H)-ONE (CCRG 81045-M-AND-B-39831), A NOVEL DRUG WITH POTENTIAL AS AN ALTERNATIVE TO DACARBAZINE1987
- Simplified Calculation of Body-Surface AreaNew England Journal of Medicine, 1987
- INVITRO AND INVIVO METHAZOLASTONE-INDUCED DNA DAMAGE AND REPAIR IN L-1210 LEUKEMIA SENSITIVE AND RESISTANT TO CHLOROETHYLNITROSOUREAS1987
- Tolerance to antineoplastic agents in children and adults.1985